Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced three upcoming poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), occurring virtually from November 9-14, 2020. The poster presentations highlight INTASYL compounds, a proprietary self-delivering RNAi therapeutic platform. Notably, findings include a study on combination treatment using INTASYL targeting TIGIT and PD-1/PD-L1, revealing enhanced tumor control. The archived presentation will be accessible in the "Investors – Events and Presentations" section of the Company's website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that CEO Dr. Gerrit Dispersyn will present at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Dr. Dispersyn's presentation will take place on September 16 at 11:30 a.m. ET. Investors can access the live webcast here, with an archived version available on the Company's website afterward. Phio focuses on developing innovative immuno-oncology therapeutics using its proprietary self-delivering RNAi platform, INTASYL™.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its Q2 2020 financial results, highlighting significant advancements in its INTASYL™ RNAi therapeutic platform. Key developments include promising preclinical data from major conferences that demonstrate the safety and efficacy of INTASYL technology in targeting immune cells for cancer treatment. As of June 30, 2020, the company had $18.9 million in cash, up from $6.9 million at year-end 2019, aiding its operations for the next 12 months. The net loss was $1.7 million, a decrease compared to $2.0 million in Q2 2019.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced at the AACR 2020 Virtual Annual Meeting promising data from a study on PH-804, a TIGIT targeting INTASYL compound. The findings indicate significant tumor growth inhibition in a colorectal carcinoma model, showing PH-804's ability to silence TIGIT mRNA and enhance immune cell activation in the tumor microenvironment. This data supports the compound's potential as a viable alternative to anti-TIGIT antibodies.